Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2025-12-24 @ 11:39 PM
NCT ID:
NCT00002051
Eligibility Criteria:
Inclusion Criteria
Concurrent Treatment:
Allowed:
* Aerosolized pentamidine.
Prior Medication:
Allowed:
* Aerosolized pentamidine.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
* AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
* Significant hepatic disease.
* Thrombocytopenia (\< 75000 platelets/mm3).
* Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to entry.
* Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
* Known hypersensitivity to thymopentin.
Prior Medication:
Excluded within 30 days of study entry:
* Immunomodulatory or experimental therapy.
* Excluded within 90 days of study entry:
* Zidovudine (AZT).
Patients must not have:
* AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
* Significant hepatic disease.
* Thrombocytopenia (\< 75000 platelets/mm3).
Patients with the following conditions are included:
* Seropositive for HIV-1 (ELISA assay) confirmed by Western blot.
* HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patient's peripheral blood monocytes (PBMC) on two separate occasions.
* HIV "wasting syndrome".
* Must voluntarily sign consent.
History of intravenous drug abuse.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00002051
Study Brief:
Protocol Section:
NCT00002051